Stratos Wealth Partners LTD. cut its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 6.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,726 shares of the medical equipment provider’s stock after selling 826 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zimmer Biomet were worth $1,400,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of ZBH. Capital Research Global Investors bought a new position in Zimmer Biomet during the first quarter valued at about $792,404,000. Johnson Investment Counsel Inc. increased its stake in Zimmer Biomet by 105.2% during the first quarter. Johnson Investment Counsel Inc. now owns 986,189 shares of the medical equipment provider’s stock valued at $123,269,000 after acquiring an additional 505,706 shares during the period. Primecap Management Co. CA increased its stake in Zimmer Biomet by 16.7% during the first quarter. Primecap Management Co. CA now owns 3,422,040 shares of the medical equipment provider’s stock valued at $345,900,000 after acquiring an additional 489,120 shares during the period. Franklin Resources Inc. increased its stake in Zimmer Biomet by 819.5% during the first quarter. Franklin Resources Inc. now owns 520,539 shares of the medical equipment provider’s stock valued at $52,604,000 after acquiring an additional 463,926 shares during the period. Finally, AXA increased its stake in Zimmer Biomet by 75.2% during the first quarter. AXA now owns 724,905 shares of the medical equipment provider’s stock valued at $73,272,000 after acquiring an additional 311,247 shares during the period. Institutional investors and hedge funds own 88.02% of the company’s stock.
NYSE:ZBH opened at $134.86 on Friday. The stock’s fifty day moving average price is $125.63 and its two-hundred day moving average price is $126.30. Zimmer Biomet Holdings Inc has a 52-week low of $74.37 and a 52-week high of $161.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.03 and a current ratio of 1.69. The company has a market cap of $27.84 billion, a price-to-earnings ratio of 74.51, a P/E/G ratio of 5.33 and a beta of 1.31.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.17. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.79 billion. During the same quarter in the prior year, the business earned $1.87 EPS. The business’s revenue for the quarter was down 9.7% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings Inc will post 3.82 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Monday, June 29th were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.71%. The ex-dividend date was Friday, June 26th. Zimmer Biomet’s dividend payout ratio is 12.20%.
ZBH has been the topic of several analyst reports. Stifel Nicolaus upped their price objective on Zimmer Biomet from $111.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Evercore ISI lowered Zimmer Biomet from an “outperform” rating to an “in-line” rating in a research note on Sunday, April 19th. Piper Sandler lowered their price objective on Zimmer Biomet from $175.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, May 11th. Citigroup upped their price objective on Zimmer Biomet from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, SVB Leerink upped their price objective on Zimmer Biomet from $136.00 to $146.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Four investment analysts have rated the stock with a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Zimmer Biomet has an average rating of “Buy” and a consensus target price of $147.65.
In related news, CEO Bryan C. Hanson purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $113.00 per share, with a total value of $113,000.00. Following the purchase, the chief executive officer now directly owns 54,568 shares in the company, valued at approximately $6,166,184. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sang Yi sold 3,000 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $125.38, for a total value of $376,140.00. Following the completion of the transaction, the insider now directly owns 2,506 shares in the company, valued at approximately $314,202.28. The disclosure for this sale can be found here. 0.44% of the stock is currently owned by corporate insiders.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Featured Story: What is the Current Ratio?
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.